“…Activating mutations in the RET protooncogene have been described in all forms of MTC. RET is a receptor tyrosine kinase (Takahashi and Cooper, 1987) which interacts with glial cell linederived neurotrophic factor (GDNF) (Durbec et al, 1996;Jing et al, 1996;Treanor et al, 1996;Trupp et al, 1996) and a newly described, related protein, neurturin (NTN) (Buj-Bello et al, 1997;Creedon et al, 1997;Klein et al, 1997), via coreceptors GDNFR-a and NTNR-a respectively. Commonly, mutations in extracellular cysteine residues encoded by exons 10 and 11 of RET are associated with two inherited MTC syndromes, familial medullary thyroid carcinoma (FMTC) and multiple endocrine neoplasia type 2A (MEN 2A) (Donis-Keller et al, 1993;Mulligan et al, 1993).…”